Research programme: PROTAC therapeutics - Arvinas
Alternative Names: ARCC-29; ARV-378; ARV-771; BET-PROTAC ARV-771; Hydrophobic Tagging small molecules - Arvinas; HyT small molecules - Arvinas; PROTAC ARV-771; PROTAC ARV-825; PROTACs - Arvinas; Protein-targeting chimeric molecules - Arvinas; Proteolysis Targeting Chimeric molecules - ArvinasLatest Information Update: 28 Jan 2025
At a glance
- Originator Arvinas
- Developer Arvinas; Yale University
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Androgen receptor degradation enhancers; Estrogen receptor alpha degradation enhancers; Proteolysis; Ubiquitin protein ligase complex modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Breast cancer; Haematological malignancies; Inflammation; Prostate cancer; Solid tumours
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Haematological-malignancies in USA
- 28 Jan 2025 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
- 10 Dec 2022 ARV 825 is still in preclinical trials for Haematological malignancies in USA